This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Resistance to targeted therapies in acute myeloid leukemia
Clinical & Experimental Metastasis Open Access 01 November 2022
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
Purchase on Springer Link
Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Legrand O, Perrot JY, Baudard M, Cordier A, Lautier R, Simonin G et al. The immunophenotype of 177 adults with acute myeloid leukemia: proposal of a prognostic score. Blood 2000; 96: 870–877.
Bross PF, Beitz J, Chen G, Chen XH, Duffy E, Kieffer L et al. Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia. Clin Cancer Res 2001; 7: 1490–1496.
Alan KB, William JK, Anthony HG, Donald M, Ann H, Archie GP et al. The addition of gemtuzumab ozogamicin to induction chemotherapy for AML improves disease free survival without extra toxicity: preliminary analysis of 1115 patients in the MRC AML15 trial. Blood 2006; 108 (11; ASH2006 abstracts): 13.
Ikemoto N, Kumar RA, Ling TT, Ellestad GA, Danishefsky SJ, Patel DJ . Calicheamicin–DNA complexes: warhead alignment and saccharide recognition of the minor groove. Proc Natl Acad Sci USA 1995; 92: 10506–10510.
Walter RB, Gooley TA, van dV V, Loken MR, van Dongen JJ, Flowers DA et al. CD33 expression and P-glycoprotein-mediated drug efflux inversely correlate and predict clinical outcome in patients with acute myeloid leukemia treated with gemtuzumab ozogamicin monotherapy. Blood 2007; 109: 4168–4170.
Sievers EL . Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukaemia in first relapse. Expert Opin Biol Ther 2001; 1: 893–901.
Buckwalter M, Dowell JA, Korth-Bradley J, Gorovits B, Mayer PR . Pharmacokinetics of gemtuzumab ozogamicin as a single-agent treatment of pediatric patients with refractory or relapsed acute myeloid leukemia. J Clin Pharmacol 2004; 44: 873–880.
Dowell JA, Korth-Bradley J, Liu H, King SP, Berger MS . Pharmacokinetics of gemtuzumab ozogamicin, an antibody-targeted chemotherapy agent for the treatment of patients with acute myeloid leukemia in first relapse. J Clin Pharmacol 2001; 41: 1206–1214.
Jeffrey R, Bassem R, Paul B, Gary D, Norman L, Jeffrey T et al. Improved remission induction rate of childhood AML: preliminary results of the AML02 trial. Blood 2005; 106 (11; ASH 2005 abstract): 275.
Coustan-Smith E, Ribeiro RC, Rubnitz JE, Razzouk BI, Pui CH, Pounds S et al. Clinical significance of residual disease during treatment in childhood acute myeloid leukaemia. Br J Haematol 2003; 123: 243–252.
Acknowledgements
We are grateful to Dr Kristine Crews for providing her input in preparing this report, to Dr Erin Schuetz for providing supporting lab materials and to Dr Donald Samulack for scientific editing. This work was supported in part by the National Institutes of Health, National Institute of General Medical Sciences Pharmacogenetics Research Network and Database (U01GM61374; http://www.pharmgkb.org) under Grant U01 GM61393; by the Cancer Center Support Grant CA-21765; and by the American Lebanese Syrian Associated Charities (ALSAC).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Lamba, J., Pounds, S., Cao, X. et al. Coding polymorphisms in CD33 and response to gemtuzumab ozogamicin in pediatric patients with AML: a pilot study. Leukemia 23, 402–404 (2009). https://doi.org/10.1038/leu.2008.185
Published:
Issue Date:
DOI: https://doi.org/10.1038/leu.2008.185
This article is cited by
-
Resistance to targeted therapies in acute myeloid leukemia
Clinical & Experimental Metastasis (2023)
-
Biological Hallmarks of Cancer in Alzheimer’s Disease
Molecular Neurobiology (2019)